Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Continues Aggressive Push into Microarray Market with New Facility

NEW YORK, Jan 10 - Agilent Technologies said Wednesday that it has opened its 15,000-square-foot DNA microarray production facility at its Santa Clara, Calif. site, five months after it announced plans to expand its microarray manufacturing program.

The facility significantly increases Agilent's current manufacturing capacity, and should enable it to ship over 1 million microarrays per year by 2002, the company said.

Agilent spokesman Doug Forsyth said that “people worked overtime” in order to get the facility online as quickly as possible. “Market pressure was such that we needed to pull all the stops out to get it completed,” he said.

Forsyth noted that the new facility is a critical development in the company’s plans to begin producing catalog arrays. While Agilent currently manufactures custom arrays to customer specifications, catalog arrays will be off-the-shelf products available to anyone who wants to buy them, Forsyth said.

Agilent’s licensing agreement with Incyte, announced earlier this week, is another major component of the move toward catalog arrays, Forsyth said. The agreement with Incyte gives Agilent access to Incyte's clone sets.

Forsyth said he expects production of catalog arrays to begin in the early summer.
The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.